Several organotin derivatives of 1,2-and 1,7-dicarba-closo-dodecaboranes were synthesized and characterized by lgsn M6ssbauer, 1H, 13C and 19Sn NMR spectroscopy.
Introduction
Boron derivatives present a potential interest in the anticancer therapy by neutron capture provided these compounds exhibit a sufficiently selective affinity towards tumour cells2. On the other hand, numerous tin derivatives exhibit promising in vitro antitumour activities 3 against as well as selectivities 4 towards some human cancer cell lines. Thus, such favourable properties can be expected from compounds combining boron and tin. In this paper we report the synthesis, characterization and in vitro antitumour activities of such compounds derived from 1,2-and 1,7-dicarba-closo-dodecaboranes 5 (ortho-and metacarborane, respectively).
Synthesis
The ortho-and meta-carboran-9-yltin dichlorides were prepared according to [5] :
(C2BloHI-9)2Hg + SnC12 --> (C2B0HI-9)2SnCI2 + Hg.
The dicarboranyltin dichlorides were transformed into the corresponding oxides by reaction with dilute aqueous sodium hydroxide:
(C2B 10H 1-9)2SNC12 + 2NaOH --> (C2B 10 H11-9)2 SnO + H20 + 2NaC1.
Both ortho-and meta-carboranyl tin oxides were reacted with 2,6-pyridine dicarboxylic acid in a 1"1 molar ratio under elimination of water. The cytotoxicity of compounds 1 to 3, together with some reference compounds, was determined in vitro against six well characterized human tumor cell lines by applying the microculture sulforhodamine B test (SRB). The compounds were tested in quadruple at 10 concentrations varying with a factor 3, ranging from 3 to 59050 ng/ml.
Concentration response curves were determined and the IDa0 (drug concentration in ng/mL at 50% growth inhibition) values were calculated. Prior to the experiments a mycoplasma test was carried out on all cell lines and found to be negative. All cell lines, except EVSA-T, were maintained in a continuous logarithmic culture in 4O M. Gielen On day 2, 100 ml of a solution with the highest drug concentration were added to the wells of column 12 and from there diluted 3-fold to column 3 by serial transfer of 100 ml using an 8 channel micropipette. The final volume of column 3 was adjusted to 200 ml with PBS. Column 2 was used for the blank. PBS was added to column 1 to diminish interfering evaporation. On day 7 the incubation was terminated by washing the plates twice with PBS. Subsequently the cells were fixed with 10% trichloroacetic acid in Milli Q water (Millipore, Etten Leur, The Netherlands) and placed at 4C for one hour. After five washings with tap water, the cells were stained for at least 15 min with 0.4% SRB, dissolved in 1% acetic acid, and subsequently washed with 1% acetic acid to remove the unbound stain. The plates were air dried and the bound protein stain was dissolved by using 150 ml 10 mmol/1 tris base. The absorbance was read at 540 nm using an automated microplate reader (Titertec, Flow Laboratories Ltd., Irvine, Scotland).
In Vivo Tests on DBA/2 mice Compound 2 was suspended in 2 % carboxymethylcellulose. The drug was administrated intraperitoneally as a single injection in a volume of 10 mL/kg. On day 0, l xl05 L 1210 cells from a stock culture suspension were injected i.p. into male DBA/2 mice. After about 24 hours treatment was started. The drug was administered by a single intraperitoneal injection to groups of 6 mice. Each drug was tested at three dose levels. The highest doses were expected to show toxicity. The untreated control group consisted of 9 mice. The average body weight of the various groups was determined on the day of treatment (day 1), on day 5 and on day 7. The survival time of the mice was recorded. The results are expressed as median survival time (MST) of treated over control mice (T/C %).
